Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa A, Chebabo A, Starling C, Pérez C, Cunha C, de Luna D, Nunes E, Zambrano G, Ferreira J, Croda J, Falavigna M, Gomes-da-Silva M, Thormann M, Cimerman S, Parahiba S, Tanni S, Bernardo W, Rodriguez-Morales A. Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals Of Clinical Microbiology And Antimicrobials 2023, 22: 67. PMID: 37550690, PMCID: PMC10408214, DOI: 10.1186/s12941-023-00623-w.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBrazilCommunicable DiseasesCOVID-19HumansHydroxychloroquineIvermectinPandemicsRitonavirSARS-CoV-2United StatesConceptsUse of hydroxychloroquineInfectious diseasesCOVID-19Treatment of outpatientsSARS-CoV-2/COVIDSevere COVID-19Evidence-based guidelinesPan American AssociationGuideline development processLack of benefitEvidence-based medicineAdverse eventsMechanical ventilationClinical manifestationsTherapeutic optionsPharmacological treatmentCOVID-19 episodeInpatient settingAmerican guidelinesGRADE systemSystematic reviewStrong recommendationsProphylaxisOutpatientsDisease